Researcher: Paul Lambert

Areas of Research Expertise
  • Human tumors
  • Prevention
  • Diagnosis
  • Prognosis
  • Epstein-Barr viurs
  • Kaposi's sarcoma-associated herpes virus
  • Human cytomegalovirus
  • Human papillomaviruses
  • Hepatitis B virus
  • Hepatitis C virus
  • Cancer
  • Leukemia
  • Stem cells
  • Molecular genetics of papillomaviruses
  • Biology of human papillomaviruses (HPV) that are implicated in human cancer
  • HPV life cycle
  • Transgenic mouse models of tumor virus action
  • HPV oncogene
  • Target cells and mechanisms of merkel cell polyomavirus infection
Web Site Paul Lambert's Department of McArdle Laboratory for Cancer Research Website
Curriculum Vitae (CV)
Current/Active Funding
  • WARF, 2006-2020, Laboratory share of royalty and licensing - Professor Paul F Lambert
  • NIH, 2013-2017, Molecular and therapeutic studies on HPV-associated anal cancer
  • NIH, 2014-2019, Virology training grant
  • NIH, 2016-2018, Molecular biology and genetics of human tumor viruses
Issued Patent(s)
  • 9,066,951 - Drugs to treat HPV infection, issued June 2015.
  • 8,158,614 - Therapeutic treatment of cancer and dysplasia of the cervix or vagina using estrogen antagonists, issued April 2012.
  • 8,012,678 - Biomarkers for human papilloma virus-associated cancer, issued September 2011.
  • 7,563,597 - Production of packaged DNA sequences, issued July 2009.
USPTO Published Applications
  • 20150297602 - Drugs to prevent HPV infection, published October 2015.
  • 20120171306 - Therapeutic treatment of cancer and dysplasia of the cervix or vagina using estrogen antagonists, published July 2012.
  • 20110301059 - Biomarkers for human papilloma virus-associated cancers, published December 2011.
  • 20110189258 - Method and compositions for inhibition of double stranded dna viruses, published August 2011.
  • 20100203164 - Therapeutic treatment of cancer and dysplasia of the cervix or vagina using estrogen antagonists, published August 2010.
Recent Publication(s)
  • The expression of miR-21 and miR-143 is deregulated by the HPV16 E7 oncoprotein and 17β-estradiol. Gómez-Gómez Y, Organista-Nava J, Ocadiz-Delgado R, García-Villa E, Leyva-Vazquez MA, Illades-Aguiar B, Lambert PF, García-Carrancá A, Gariglio P. Int J Oncol. 2016 Jun 9. doi: 10.3892/ijo.2016.3575. [Epub ahead of print]

  • Role of Ultraviolet Radiation in Papillomavirus-Induced Disease. Uberoi A, Yoshida S, Frazer IH, Pitot HC, Lambert PF. PLoS Pathog. 2016 May 31;12(5):e1005664. doi: 10.1371/journal.ppat.1005664. eCollection 2016 May.

  • Identifying the Target Cells and Mechanisms of Merkel Cell Polyomavirus Infection. Liu W, Yang R, Payne AS, Schowalter RM, Spurgeon ME, Lambert PF, Xu X, Buck CB, You J. Cell Host Microbe. 2016 Jun 8;19(6):775-87. doi: 10.1016/j.chom.2016.04.024. Epub 2016 May 19.

  • Loss of Dependence on Continued Expression of the Human Papillomavirus 16 E7 Oncogene in Cervical Cancers and Precancerous Lesions Arising in Fanconi Anemia Pathway-Deficient Mice. Park S, Park JW, Pitot HC, Lambert PF. MBio. 2016 May 17;7(3). pii: e00628-16. doi: 10.1128/mBio.00628-16.

View Paul Lambert's publications at PubMed.
Recent Artistic Works
  • Intra-University Collaboration: Cell and Regenerative Biology, Pathology, Biostatistics and Medical Informatics, Surgery
Research Tools
Research Facilities
E-mail Address [email protected]
Phone Number 608-262-8533
Current University UW–Madison
Department Oncology
Title Professor and Chair
Other Appointments
Address Line 1 6459 Wisconsin Institutes for Medical Research
Address Line 2 1111 Highland Avenue
City Madison
State WI
Zip Code 53705
Bachelor's Degree B.S., University of Massachusetts, Biochemistry, 1979
Master's Degree
PhD Ph.D., UW–Madison, Biochemistry, 1985
Other Degrees
Technologies Available for Licensing Cryopreserved Head and Neck Cancer Tumorgrafts and Related Cell Strains

Production of Packaged DNA Sequence

HPV-Positive Biomarkers for Cervical and Head and Neck Cancers

Clonal Lines of Human Cervical Epithelial Cells That Harbor Human Papillomavirus Type 16

Small Molecule Therapeutics to Inhibit HPV Infection

Using Anti-Estrogens to Treat Cervical or Vaginal Cancer and Dysplasia